178 related articles for article (PubMed ID: 37108276)
1. Circulating CD137
Cirillo A; Zizzari IG; Botticelli A; Strigari L; Rahimi H; Scagnoli S; Scirocchi F; Pernazza A; Pace A; Cerbelli B; d'Amati G; Marchetti P; Nuti M; Rughetti A; Napoletano C
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108276
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis.
Cirillo A; Marinelli D; Romeo U; Messineo D; De Felice F; De Vincentiis M; Valentini V; Mezi S; Valentini F; Vivona L; Chiavassa A; Cerbelli B; Santini D; Bossi P; Polimeni A; Marchetti P; Botticelli A
BMC Cancer; 2024 Apr; 24(1):430. PubMed ID: 38589857
[TBL] [Abstract][Full Text] [Related]
3. CD137
Gelibter A; Asquino A; Strigari L; Zizzari IG; Tuosto L; Scirocchi F; Pace A; Siringo M; Tramontano E; Bianchini S; Bellati F; Botticelli A; Paoli D; Santini D; Nuti M; Rughetti A; Napoletano C
J Transl Med; 2024 Apr; 22(1):329. PubMed ID: 38570798
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors in head and neck squamous cell carcinoma: A systematic review of phase-3 clinical trials.
Poulose JV; Kainickal CT
World J Clin Oncol; 2022 May; 13(5):388-411. PubMed ID: 35662989
[TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab in the first-line treatment of advanced head and neck cancer.
de Sousa LG; Ferrarotto R
Expert Rev Anticancer Ther; 2021 Dec; 21(12):1321-1331. PubMed ID: 34689660
[TBL] [Abstract][Full Text] [Related]
6. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma.
Haddad RI; Seiwert TY; Chow LQM; Gupta S; Weiss J; Gluck I; Eder JP; Burtness B; Tahara M; Keam B; Kang H; Muro K; Albright A; Mogg R; Ayers M; Huang L; Lunceford J; Cristescu R; Cheng J; Mehra R
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35217573
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D;
Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945
[TBL] [Abstract][Full Text] [Related]
8. The association between body mass index and efficacy of pembrolizumab as second-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Zhang X; Rui M; Lin C; Li Z; Wei D; Han R; Ju H; Ren G
Cancer Med; 2023 Feb; 12(3):2702-2712. PubMed ID: 35975731
[TBL] [Abstract][Full Text] [Related]
9. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
[TBL] [Abstract][Full Text] [Related]
10. The effect of opioids on the efficacy of immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck.
Scheff NN; Nilsen ML; Li J; Harris AL; Acharya R; Swartz A; Hsieh RW; Anderson JL; Ferris RL; Menk AV; Delgoffe GM; Zandberg DP
Oral Oncol; 2023 May; 140():106363. PubMed ID: 36963232
[TBL] [Abstract][Full Text] [Related]
11. PD1 blockade enhances K
Newton HS; Gawali VS; Chimote AA; Lehn MA; Palackdharry SM; Hinrichs BH; Jandarov R; Hildeman D; Janssen EM; Wise-Draper TM; Conforti L
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060146
[TBL] [Abstract][Full Text] [Related]
12. Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.
Curti BD; Koguchi Y; Leidner RS; Rolig AS; Sturgill ER; Sun Z; Wu Y; Rajamanickam V; Bernard B; Hilgart-Martiszus I; Fountain CB; Morris G; Iwamoto N; Shimada T; Chang S; Traber PG; Zomer E; Horton JR; Shlevin H; Redmond WL
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837055
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States.
Borse RH; Ramakrishnan K; Gandhi J; Dhankhar P; Chirovsky D
J Med Econ; 2022; 25(1):954-965. PubMed ID: 35765888
[TBL] [Abstract][Full Text] [Related]
14. Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer.
Zizzari IG; Di Filippo A; Botticelli A; Strigari L; Pernazza A; Rullo E; Pignataro MG; Ugolini A; Scirocchi F; Di Pietro FR; Rossi E; Gelibter A; Schinzari G; D'Amati G; Rughetti A; Marchetti P; Nuti M; Napoletano C
Clin Cancer Res; 2022 Mar; 28(5):1027-1037. PubMed ID: 34980602
[TBL] [Abstract][Full Text] [Related]
15. Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.
Harrington KJ; Kong A; Mach N; Chesney JA; Fernandez BC; Rischin D; Cohen EEW; Radcliffe HS; Gumuscu B; Cheng J; Snyder W; Siu LL
Clin Cancer Res; 2020 Oct; 26(19):5153-5161. PubMed ID: 32669371
[TBL] [Abstract][Full Text] [Related]
16. The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
Ghanizada M; Jakobsen KK; Grønhøj C; von Buchwald C
Oral Oncol; 2019 Mar; 90():67-73. PubMed ID: 30846179
[TBL] [Abstract][Full Text] [Related]
17. Low free triiodothyronine and immune-related hyperthyroidism are associated with overall and progression-free survival in head and neck squamous cell carcinoma treated with pembrolizumab.
Haas M; Lein A; Fuereder T; Schnoell J; Brkic FF; Campion NJ; Liu DT; Kadletz-Wanke L; Heiduschka G; Jank BJ
Int Immunopharmacol; 2023 Oct; 123():110799. PubMed ID: 37598631
[TBL] [Abstract][Full Text] [Related]
18. Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma.
Desilets A; Soulières D
Expert Opin Drug Saf; 2020 Aug; 19(8):927-934. PubMed ID: 32458764
[TBL] [Abstract][Full Text] [Related]
19. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
[TBL] [Abstract][Full Text] [Related]
20. Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab - the randomized phase 2 FOCUS trial.
Brandt A; Schultheiss C; Klinghammer K; Schafhausen P; Busch CJ; Blaurock M; Hinke A; Tometten M; Dietz A; Müller-Richter U; Hahn D; Alt J; Stein A; Binder M
Front Oncol; 2024; 14():1283266. PubMed ID: 38384801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
